AP NEWS
ADVERTISEMENT
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

IVERIC bio to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 17, 2020 GMT

NEW YORK--(BUSINESS WIRE)--Dec 17, 2020--

IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Glenn P. Sblendorio, Chief Executive Officer and President, will present an overview of the Company at the 39 th Annual J.P. Morgan Healthcare Conference in a virtual session on Thursday, January 14, 2021 at 2:50 p.m. Eastern Time.

ADVERTISEMENT

Investors and the general public are invited to listen to a live webcast of the presentation on the Investor / Events & Presentations section of the IVERIC bio website at www.ivericbio.com. An archived replay of the webcast will be available on the Company’s website immediately following the conference and for at least two weeks thereafter.

About IVERIC bio

IVERIC bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with significant unmet medical needs. The Company is currently developing both therapeutic product candidates for age-related retinal diseases and gene therapy product candidates for orphan inherited retinal diseases. Vision is Our Mission. For more information on the Company please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release about IVERIC bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors. Any forward-looking statements represent IVERIC bio’s views only as of the date of this press release. IVERIC bio anticipates that subsequent events and developments will cause its views to change. While IVERIC bio may elect to update these forward-looking statements at some point in the future, IVERIC bio specifically disclaims any obligation to do so.

ADVERTISEMENT

ISEE-G

View source version on businesswire.com:https://www.businesswire.com/news/home/20201217005168/en/

CONTACT: Investors:

IVERIC bio

Kathy Galante, 212-845-8231

Vice President, Investor Relations and Corporate Communications

kathy.galante@ivericbio.com

or

Media:

SmithSolve

Alex Van Rees, 973-442-1555 ext. 111

alex.vanrees@smithsolve.com

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: RESEARCH FDA CLINICAL TRIALS OTHER HEALTH BIOTECHNOLOGY PHARMACEUTICAL HEALTH OPTICAL SCIENCE OTHER SCIENCE

SOURCE: IVERIC bio, Inc.

Copyright Business Wire 2020.

PUB: 12/17/2020 08:00 AM/DISC: 12/17/2020 08:01 AM

http://www.businesswire.com/news/home/20201217005168/en